GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Gross Margin %

CanSino Biologics (HKSE:06185) Gross Margin % : 59.55% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. CanSino Biologics's Gross Profit for the three months ended in Mar. 2024 was HK$73.9 Mil. CanSino Biologics's Revenue for the three months ended in Mar. 2024 was HK$124.1 Mil. Therefore, CanSino Biologics's Gross Margin % for the quarter that ended in Mar. 2024 was 59.55%.


The historical rank and industry rank for CanSino Biologics's Gross Margin % or its related term are showing as below:

HKSE:06185' s Gross Margin % Range Over the Past 10 Years
Min: -253.78   Med: 3.73   Max: 69.82
Current: -241.82


During the past 8 years, the highest Gross Margin % of CanSino Biologics was 69.82%. The lowest was -253.78%. And the median was 3.73%.

HKSE:06185's Gross Margin % is ranked worse than
99.09% of 987 companies
in the Drug Manufacturers industry
Industry Median: 46.23 vs HKSE:06185: -241.82

CanSino Biologics had a gross margin of 59.55% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for CanSino Biologics was 0.00% per year.


CanSino Biologics Gross Margin % Historical Data

The historical data trend for CanSino Biologics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Gross Margin % Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - 25.56 69.82 -18.10 -253.78

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.17 1,021.63 504.32 -518.39 59.55

Competitive Comparison of CanSino Biologics's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Gross Margin % falls into.



CanSino Biologics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

CanSino Biologics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-958.2 / 377.553
=(Revenue - Cost of Goods Sold) / Revenue
=(377.553 - 1335.724) / 377.553
=-253.78 %

CanSino Biologics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=73.9 / 124.145
=(Revenue - Cost of Goods Sold) / Revenue
=(124.145 - 50.222) / 124.145
=59.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CanSino Biologics  (HKSE:06185) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CanSino Biologics had a gross margin of 59.55% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


CanSino Biologics Gross Margin % Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (HKSE:06185) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (HKSE:06185) Headlines

No Headlines